- Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy
-
Kwon YS, Nam JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT
- KMID: 1779203
- J Korean Med Sci.
- 2009 Aug;24(4):679-683.
- doi: 10.3346/jkms.2009.24.4.679
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between... -
- CITED
-
- Close
- SHARE
-
- Close
- Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
-
Martin JY, Urban RR, Liao JB, Goff BA
- KMID: 2374249
- J Gynecol Oncol.
- 2016 Sep;27(5):e47.
- doi: 10.3802/jgo.2016.27.e47
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
-
Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT, Kim S
- KMID: 2070217
- Yonsei Med J.
- 2014 Nov;55(6):1664-1671.
- doi: 10.3349/ymj.2014.55.6.1664
PURPOSE: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status. MATERIALS AND METHODS: One... -
- CITED
-
- Close
- SHARE
-
- Close
- An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)
-
Lee SW, Kim YM, Kim YT, Kang SB
- KMID: 2413442
- J Gynecol Oncol.
- 2017 May;28(3):e26.
- doi: 10.3802/jgo.2017.28.e26
OBJECTIVE: This phase I study aimed to determine the maximum tolerated dose (MTD) of Genexol-PM, when combined with carboplatin, as a first-line treatment in patients with advanced ovarian cancer. METHODS: This... -
- CITED
-
- Close
- SHARE
-
- Close
